Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Biogen

BIIB Healthcare Unknown Updated August 01, 2026
$202.89
52W $124.56 – $219.72
61/100
$29.99B
35.7
0.16
AI Committee Verdict
Buy
Conviction: Moderate · 67% agreement · 6 analysts
+1.4%
-2.9%
0.49:1
Moderate
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is BIIB Bullish or Bearish?

Bullish. Innellis AI committee rates Biogen (BIIB) Buy with a composite score of 61/100 , based on 6 analysts with 67% agreement. Last updated August 01, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.10 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.90 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is price-to-book of 1.4x is a discount to asset value. The main limiting factor is eps declining -8.1% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.4x is a discount to asset value — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • EPS declining -8.1% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 01, 2026
Overall Committee Score
61/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 17%
of 93 Healthcare peers
Value Analyst bullish
70 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.4x is a discount to asset value
Growth Analyst neutral
44 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -8.1% YoY despite any revenue growth
Technical Analyst bullish
68 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 45 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.5 to 60.9.

Analyst-level changes:
  • Macro Analyst: stance neutral->bullish; score 58->70 (+12).
  • News Analyst: +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).

Comparing 2026-07-31 to 2026-08-01 (1 day apart).

Technical Analysis

RSI (14)
48.3
Neutral
MACD Histogram
0.154
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$197.00
Resistance
$205.76
Bollinger %B
0.51
Inside Bands
Price vs Moving Averages
EMA 9
$204.22 Below
EMA 21
$203.36 Below
EMA 50
$200.32 Above
EMA 200
$184.22 Above

Fundamental Analysis

Valuation
72
Growth
55
Profitability
0
Financial Health
94
Cash Flow
38
Valuation
P/E Ratio 35.7×
P/B Ratio 1.59×
PEG Ratio -0.78
Dividend Yield 0.00%
52W High $219.72
52W Low $124.56
Quality & Growth
ROE 7.1%
ROA 4.4%
Gross Margin 67.7%
Operating Margin 12.8%
Revenue Growth YoY
Debt / Equity 0.44
AI Fundamental Assessment
P/E ratio of 35.7 (rich relative to a 15-40x range); Price-to-book of 1.6x; PEG ratio of -0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.44; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (20.10); Most recent quarter beat estimates by 19.8%; 5 consecutive earnings beats; EPS growth decelerating (+79.4% -> +0.8% QoQ); Average YoY EPS growth of -34.2%; Analyst estimates rising over recent quarters
Get the Full BIIB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore BIIB Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime